View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 16, 2021

EMA starts review of GSK and Vir’s monoclonal antibody for Covid-19

The European Medicines Agency (EMA) has started a review of GlaxoSmithKline (GSK) and Vir Biotechnology’s investigational dual-action SARS-CoV-2 monoclonal antibody VIR-7831 (GSK4182136) for treating Covid-19 patients.

The European Medicines Agency (EMA) has started a review of GlaxoSmithKline (GSK) and Vir Biotechnology’s investigational dual-action SARS-CoV-2 monoclonal antibody VIR-7831 (GSK4182136) for treating Covid-19 patients.

VIR-7831 is an investigational dual-action antibody designed for increasing concentration in the lungs to guarantee optimal penetration into SARS-CoV-2 affected airway tissues.

The antibody treatment is intended for adults and adolescents aged 12 years and above weighing at least 40kg who do not need supplementary oxygen and are at high risk of progressing to severe Covid-19.

EMA’s Committee for Human Medicinal Products (CHMP) is conducting the review and will offer recommendations across the EU for national authorities to make evidence-based decisions for the early use of the medicine before obtaining formal marketing authorisation.

The review will have interim analysis efficacy and safety data from the phase III COMET-ICE trial of VIR-7831 monotherapy for early Covid-19 treatment in adult subjects at an increased risk of hospitalisation.

Data from the study showed that subjects receiving VIR-7831 in the trial had an 85% reduction in hospitalisation or death versus placebo, the primary endpoint of the study.

Last month, the Independent Data Monitoring Committee (IDMC) recommended stopping subject enrolment in the trial owing to evidence of profound efficacy.

Recently, the Australian Therapeutic Goods Administration (TGA) granted a provisional determination to VIR-7831 facilitating a formal and transparent mechanism for expediting the registration of promising new medicines with preliminary clinical data.

In the same month, GSK and Vir had applied to the US Food and Drug Administration (FDA) for emergency use authorization (EUA) of VIR-7831 (GSK4182136) to treat Covid-19.

Separately, Merck has decided to discontinue the development of MK-7110, formerly known as CD24Fc, for treating hospitalised Covid-19 patients.

In December last year, the company acquired MK-7110 through its acquisition of OncoImmune.

Merck Research Laboratories chief medical officer, senior vice-president and global clinical development head Dr Roy Baynes said: “Merck’s commitment from the outset of the pandemic has been to deploy our expertise and capabilities where they can have the most impact.

“Merck is now focusing its efforts on advancing molnupiravir, which, as an oral medicine for outpatient use, represents a promising potential new approach and on accelerating production of Johnson & Johnson’s Covid-19 vaccine.”

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU